Research presented by Invitae at the American Society of Human Genetics Meeting Pushes Science and Practice of Genetics Forward
Research presented by Invitae at the American Society of Human Genetics Meeting Pushes Science and Practice of Genetics Forward -- Advances in classification, new approaches to genetics in cancer and implications of primary and secondary findings for clinical care among wide-ranging data presentations -- |
[17-October-2019] |
HOUSTON, Oct. 17, 2019 /PRNewswire/ -- Researchers from Invitae Corporation (NYSE: NVTA), a leading medical genetics company, are presenting data showing the increasing utility of genetic information at the American Society of Human Genetics (ASHG) annual meeting this week, ranging from comprehensive screening for cancer patients, to appropriate clinical follow up for women using non-invasive prenatal screening, to the limitations of direct to consumer genetic screening health reports.
The company's research includes three platform presentations and multiple poster sessions, many performed in collaboration with leading academic researchers. Among the data presented is a study evaluating the utility of combined germline testing and tumor profiling (somatic testing) in cancer patients. Germline and somatic testing are increasingly used in precision treatment of people with cancer, although frequently are ordered separately in clinical practice. Data presented at the meeting shows a substantial number of patients with medically significant variants in hereditary cancer syndrome genes in their tumor profile carry the same variant in their germline, thereby establishing a previously unknown risk of hereditary cancer and suggesting the value of combined or concurrent testing to inform precision medicine approaches. "The research we are presenting at this year's ASHG meeting provides meaningful insight into both the science and practice of genetics, helping identify how we as clinicians can better use deep genetic insights to help a wide array of patients, whether they are cancer patients, women having a child or healthy adults seeking to better understand their risk of disease," said Robert Nussbaum, M.D., chief medical officer of Invitae. "We are proud and grateful to be able to join our colleagues from across genetic medicine in meaningful conversations that push genetic medicine forward." Following are research from the company and collaborators to be presented at the meeting: Wednesday, October 16: Poster presentation #819W | 2:00 – 3:00 pm Poster presentation #2427W | 2:00 – 3:00 pm Poster presentation #606W | 3:00 – 4:00 pm Thursday, October 17: Platform presentation #235 | 5:00 pm, Room 370A, Level 3 Poster presentation #763T | 2:00 – 3:00 pm Poster presentation #1399T | 2:00 – 3:00 pm Friday, October 18: Platform presentation #264 | 9:00 am, Room 361D, Level 3 Platform presentation #265 | 9:15 am, Room 361D, Level 3 Poster presentation #698F | 2:00 – 3:00 pm About Invitae Safe Harbor Statements Contact: View original content to download multimedia:http://www.prnewswire.com/news-releases/research-presented-by-invitae-at-the-american-society-of-human-genetics-meeting-pushes-science-and-practice-of-genetics-forward-300940213.html SOURCE Invitae Corporation | ||
Company Codes: NYSE:NVTA |
© 2019 PR Newswire. All Rights Reserved.